Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
32
Active, not recruiting, industry sponsors, Immunology and inflammation, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting150
- Completed727
32 trials
Showing 1 to 25, recently updated first.
- A Trial of SHR-1139 in Healthy VolunteersActive, not recruiting
Atridia Pty Ltd.Industry
NCT07078695 · 24 participants (planned) · Start Aug 19, 2025 · Primary completion Nov 9, 2026
Drug: SHR-1139 Injection; SHR-1139 Injection and 1 more · For: Psoriasis
Sites: Perth, Australia
- A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06576271 · 143 participants · Start Sep 2, 2024 · Primary completion Feb 1, 2028
Drug: GSK4527363; Placebo matching GSK4527363 and 1 more · For: Systemic Lupus Erythematosus
Sites: Las Vegas, Nevada; Columbus, Ohio; Buenos Aires, Argentina · 23 sites in all
- Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic ArthritisActive, not recruiting
LAPIX Therapeutics Inc.Industry
NCT06628206 · 48 participants (planned) · Start Dec 15, 2024 · Primary completion Nov 15, 2026
Drug: LPX-TI641; Placebo · For: Rheumatoid Arthritis (RA); Psoriatic Arthritis (PsA)
Sites: Homestead, Florida; South Miami, Florida; Fargo, North Dakota · 6 sites in all
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruiting
Alpine Immune Sciences, Inc.Industry
NCT05732402 · 72 participants · Start Mar 15, 2023 · Primary completion Mar 2, 2028
Drug: Povetacicept · For: Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Valencia, California · 30 sites in all
- A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 InjectionsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07232004 · 142 participants (planned) · Start Nov 24, 2025 · Primary completion May 2028
Drug: ABBV-547; ABBV-547 Placebo · For: Healthy Volunteer; Psoriasis
Sites: Birmingham, Alabama; Bryant, Arkansas; Anaheim, California · 20 sites in all
- An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisActive, not recruiting
Apogee Therapeutics, Inc.Industry
NCT07027527 · 86 participants · Start Jun 4, 2025 · Primary completion Aug 29, 2026
Drug: APG777; APG990 and 1 more · For: Atopic Dermatitis
Sites: Darlinghurst, Australia; Kogarah, Australia; Westmead, Australia · 20 sites in all
- Evaluate the Safety, Tolerability of BAT6026Active, not recruiting
Bio-Thera SolutionsIndustry
NCT06094179 · 33 participants (planned) · Start Nov 9, 2023 · Primary completion Dec 31, 2026
Drug: Monoclonal antibody BAT6026; sodium chloride injection · For: Dermatitis, Atopic
Sites: Beijing, China
- A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05835986 · 70 participants (planned) · Start Dec 18, 2023 · Primary completion Nov 30, 2027
Drug: RO7507062; Tocilizumab · For: Systemic Lupus Erythematosus
Sites: Barranquilla, Colombia; Medellín, Colombia; Paris, France · 18 sites in all
- A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusActive, not recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.Industry
NCT06530849 · 20 participants · Start Aug 22, 2024 · Primary completion Feb 1, 2027
Drug: GC012F Injection · For: Refractory Systemic Lupus Erythematosus
Sites: Shanghai, China; Wuhan, China
- A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07048197 · 27 participants (planned) · Start Jun 20, 2025 · Primary completion Nov 1, 2028
Drug: Rapcabtagene autoleucel · For: Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Sites: Bordeaux, France; Brest, France; Le Kremlin-Bicêtre, France · 12 sites in all
- An Open-label Study of CND261 in Seropositive Rheumatoid ArthritisActive, not recruiting
Candid TherapeuticsIndustry
NCT07052032 · 47 participants (planned) · Start Jun 16, 2025 · Primary completion Jun 1, 2027
Drug: CND261 · For: Rheumatoid Arthritis
Sites: Chisinau, Moldova; Kyiv, Ukraine
- Study of GS-0151 in Participants With Rheumatoid ArthritisActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06902519 · 65 participants · Start May 14, 2025 · Primary completion Mar 2027
Drug: GS-0151; Placebo · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; La Jolla, California; Palo Alto, California · 35 sites in all
- Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed ConditionsActive, not recruiting
Oscotec Inc.Industry
NCT07675226 · 48 participants (planned) · Start Jul 10, 2026 · Primary completion Dec 31, 2026
Drug: SKI-O-703 API in Capsules; SKI-O-703 Formulated Granules in Capsules · For: Bioequivalence Study in Healthy Subjects; Immune Thrombocytopenia (ITP); Rheumatoid Arthritis (RA)
Sites: Seongnam-si, South Korea
- A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy ParticipantsActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06681181 · 48 participants · Start Nov 18, 2024 · Primary completion Apr 23, 2026
Drug: GSK4528287; Placebo · For: Colitis, Ulcerative
Sites: Cambridge, United Kingdom
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Active, not recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT05869955 · 270 participants (planned) · Start Sep 13, 2023 · Primary completion Aug 29, 2028
Drug: CC-97540; Fludarabine and 2 more · For: Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathy; Systemic Sclerosis and 1 more
Sites: Aurora, Colorado; Denver, Colorado; Jacksonville, Florida · 46 sites in all
- Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusActive, not recruiting
Autolus LimitedIndustry
NCT06333483 · 16 participants · Start Feb 2, 2024 · Primary completion Sep 2027
Drug: Obecabtagene autoleucel (obe-cel) · For: Systemic Lupus Erythematosus
Sites: Barcelona, Spain; Valencia, Spain; Cambridge, United Kingdom · 6 sites in all
- A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)Active, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06799520 · 30 participants (planned) · Start Mar 17, 2025 · Primary completion Oct 19, 2026
Drug: VIS171 · For: Systemic Lupus Erythematosus (SLE); Alopecia Areata (AA); Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Sites: Sofia, Bulgaria; Chisinau, Moldova; Bucharest, Romania · 6 sites in all
- A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic DiseaseActive, not recruiting
SynthekineIndustry
NCT06544330 · 48 participants (planned) · Start Apr 29, 2025 · Primary completion Apr 2028
Drug: SYNCAR-001; STK-009 · For: Systemic Lupus Erythematosus; Lupus Nephritis; Systemic Sclerosis
Sites: Scottsdale, Arizona; Hackensack, New Jersey; Manhasset, New York · 6 sites in all
- An Ascending Dose Study of PIT565 in Participants With Rheumatoid ArthritisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07029555 · 57 participants (planned) · Start Jun 12, 2025 · Primary completion May 15, 2028
Drug: PIT565 · For: Rheumatoid Arthritis
Sites: Pilar, Argentina; CABA, Argentina; Sofia, Bulgaria · 16 sites in all
- An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).Active, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06335979 · 54 participants (planned) · Start Oct 8, 2024 · Primary completion Nov 17, 2027
Drug: PIT565 · For: Systemic Lupus Erythematosus, SLE
Sites: Beijing, China; Berlin, Germany; Mainz, Germany · 11 sites in all
- Trial of HSK44459 Cream for the Management Plaque PsoriasisPivotal-lookingActive, not recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07623486 · 180 participants (planned) · Start May 22, 2026 · Primary completion Mar 2027
Drug: HSK44459 Cream; Vehicle · For: Psoriasis
Sites: Hangzhou, China
- A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's DiseaseActive, not recruiting
Palisade BioIndustry
NCT07428096 · 6 participants (planned) · Start Oct 17, 2025 · Primary completion Jan 30, 2026
Drug: PALI-2108 · For: Fibrostenotic Crohn's Disease
Sites: Montreal, Canada
- A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesActive, not recruiting
Century Therapeutics, Inc.Industry
NCT06255028 · 6 participants · Start Feb 6, 2025 · Primary completion Aug 2028
Drug: CNTY-101; IL-2 and 1 more · For: Systemic Lupus Erythematosus; Lupus Nephritis; Idiopathic Inflammatory Myopathies and 1 more
Sites: Los Angeles, California; Sacramento, California; Chicago, Illinois · 6 sites in all
- AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusActive, not recruiting
Artiva Biotherapeutics, Inc.Industry
NCT06265220 · 51 participants (planned) · Start Apr 3, 2024 · Primary completion Aug 2027
Drug: AB-101; Cyclophosphamide and 3 more · For: Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus and 1 more
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 9 sites in all
- Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult ParticipantsActive, not recruiting
Generate BiomedicinesIndustry
NCT06920693 · 40 participants (planned) · Start Mar 27, 2025 · Primary completion Aug 30, 2026
Drug: GB-7624; Placebo · For: Atopic Dermatitis (AD)
Sites: Herston, Australia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.